Co-administration of an ACE-inhibitor (moexipril) and hormonal replacement therapy in postmenopausal women

Journal of Human Hypertension

Volumn 13, Issue 5, 1999, Pages 337-342

  Koch, B ^a   Oparil, S ^b   Stimpel, Michael ^a  

^a Schwarz Pharma AG   (Germany)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Hormonal replacement therapy; Moexipril; Postmenopausal women

Indexed keywords

CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; FIBRINOGEN; GESTAGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MOEXIPRIL; TRIACYLGLYCEROL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEADACHE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0033066224     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000815     Document Type: Article

References (37)

1. Bush TL. Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy. Eur Heart J 1996; 17: 9-14.
2. Falkeborn M et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992; 99 (10): 821-828.
3. Hazzard WR. Interdisciplinary review of estrogen replacement therapy: Estrogen replacement and cardiovascular disease: Serum lipids and blood pressure effects. Am J Obstet Gynecol 1989; 161 (6S): 1847-1853.
4. Nait M, Hayashi T, Iguchi A. New approaches to the prevention of atherosclerosis. Drugs 1995; 50: 440-453.
5. Schneider HP, Birkhäuser M. Does HRT modify risk of gynecological cancers? Int J Fertil Menopausal Stud 1995; 40 (Suppl 1): 40-53.
6. Mayeaux EJ Jr, Johnson C. Current concepts in postmenopausal hormone replacement therapy. J Fam Pract 1996; 43: 69-75.
7. Samsioe G. Hormone replacement therapy and cardiovascular disease. Int J Fertil Menopausal Stud 1993; 38: 23-29.
8. Lip G, Beevers M, Churchill D, Beevers DG. Do clinicians prescribe HRT for hypertensive postmenopausal women? Br J Clin Pract 1995; 49: 61-64.
9. Lip GY, Beevers M, Churchill D, Beevers DG. Hormone replacement therapy and blood pressure in hypertensive women. J Hum Hypertens 1994; 8: 491-494.
10. Sarubbi B, Ducceschi V, Russo B, Di Micco G, Iacono A. Sex hormones, glycolipid metabolism, and atherogenesis. Minerva Med 1995; 86: 265-273.
11. Renard E, Bringer J, Jaffiol C. Sex steroids. Effects on the carbohydrate metabolism before and after menopause. Presse Med 1993; 22: 431-435.
12. Kleerekoper M, Sullivan JM. Osteoporosis as a model for the long-term clinical con-sequences of the menopause. Prog Cardiovasc Dis 1995; 38: 181-188.
13. Lip GY, Beevers G, Zarifis J. Hormone replacement therapy and cardiovascular risk: the cardiovascular physicians' viewpoint. J Intern Med 1995; 238: 389-399.
14. Tonstad S et al. Efficacy of sequential hormone replacement therapy in the treatment of hypercholesterolaemia among postmenopausal women. J Intern Med 1995; 238: 39-47.
15. Habiba M, Akkad A, al-Azzawi F. Effect of a new cyclical sequential postmenopausal HRT on lipoprotein, apoprotein and thrombophilia profile. Eur J Obstet Gynecol Repord Biol 1995; 62: 89-94.
16. Scarabin PY et al. Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb Haemost 1993; 70: 584-587.
17. Dallongeville J et al. Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women. Atherosclerosis 1995; 118: 123-133.
18. Drayer I, Stimpel M, Fox AAL, Weber MA. The antihypertensive properties of the angiotensin converting enzyme inhibitor moexipril given alone or in combination with a low dose of a diuretic. Am J Therap 1995; 2: 525-531.
19. Stimpel M et al. Moexipril versus captopril in patients with mild to moderate hypertension. Cardiovasc Pharmacol 1996; 28: 769-773.
20. White WB, Stimpel M. Long-term safety and efficacy of moexipril alone and in combination with hydrochlorothiazide in elderly patients with hypertension. J Hum Hypertens 1995; 9: 879-884.
21. Persson B, Stimpel M. Evaluation of the antihypertensive efficacy and tolerability of moexipril, a nes ACE inhibitor, compared to hydrochlorothiazide in elderly patients. Eur J Clin Pharmacol 1996; 50: 259-264.
22. Stimpel M, Bonn R, Koch B, Dickstein K. Pharmacology and clinical use of the new ACE-inhibitor moexipril. Cardiovasc Drug Rev 1995; 13: 211-229.
23. Black H. Metabolic considerations in the choice of therapy for the patient with hypertension. Am Heart J 1991; 121: 707-715.
24. Middeke M, Krone W. Effects of perindopril on serum lipids in hypertensive patients with hyperlipemia. J Cardiovasc Pharmacol 1994; 23: 629-631.
25. Haverkate F, Thompson SG, Duckert F. Haemostasia factors in angina pectoris; relation to gender, age and acute-phase reaction. Results of the ECAT Angina Pectoris Study Group. Thromb Haemost 1995; 73: 561-567.
26. Heinrich J, Assmann G. Fibrinogen and cardiovascular risk. J Cardiovasc Risk 1995; 2: 197-205
27. Lindoff C et al. Passage of the menopause is followed by haemostatic changes. Maturitas 1993; 17: 17-22.
28. Meilahn EN et al. Association of sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in postmenopausal women. Am J Epidemiol 1996; 143: 159-166.
29. Baller D et al. Klinische Bedeutung des kardiovaskulären Risikofaktors Fibrinogen in der Sekundärprävention. Versicherungsmedizin 1995; 47: 55-60.
30. Folsom AR. Epidemiology of fibrinogen. Eur Heart J 1995; 16 (Suppl A): 21-24.
31. De Soever E et al. Relation of fibrinogen to lifestyles and to cardiovascular risk factors in a working population. Int J Epidemiol 1995; 24: 915-921.
32. Stefanick ML et al. Distribution and correlates of plasma fibrinogen in middle-aged women. Initial findings of the Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Arterioscler Thromb Vasc Biol 1995; 15: 2085-2093.
33. Fogari R et al. Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients. Br J Clin Pharmacol 1995; 39: 471-476.
34. Morice AH, Brown MJ, Higenbottam T. Cough associated with angiotensin converting enzyme inhibition. J Cardiovasc Pharmacol 1989; 13 (Suppl 3): S59-S62.
35. Uzuballis RI, Frewin DB, Bushell MK, McEvoy RD. The effect of angiotensin converting enzyme inhibitors (ACE-I) and selective beta 1-antagonists on bronchial reactivity and the cough reflex in man. Eur J Clin Pharmacol 1989; 37: 467-470.
36. Strocchi E, Valtancoli G, Ambrosioni E. The incidence of cough during treatment with angiotensin converting enzyme inhibitors. J Hypertens 1989; 7: S308-S309.
37. Fuller RW. Cough associated with angiotensin-converting enzyme inhibitors. J Hum Hypertens 1989; 3 (Suppl 1): 159-161.